Gene expression
Is ITGAL a gastric-cancer immune biomarker?
Open access · cc by · source: Europe PMC
ITGAL mRNA is higher in 408 GC vs 211 normal samples (AUC 0.798), tracks CD8/macrophage infiltrates and PD1, and worse OS on KM plotter (HR 1.25 and 1.47) across 1,065 tumors.
Study at a glance
- Design
- Computational / modelling — TCGA/GEPIA/TIMER/UALCAN/KM-plotter/TISIDB of ITGAL in gastric cancer plus IHC, qRT-PCR, and Western blot on 10 paired tumors
- N
- N=1065 · KM plotter 1,065 GC samples (mean follow-up 33 months); GEPIA 408 tumors vs 211 normals; 10 paired tissues for qPCR/WB; TCGA matched n=27
- Population
- Stomach adenocarcinoma bulk transcriptomes (TCGA/GTEx) and 10 paired gastric-cancer surgical tissues
- Outcome
- ITGAL expression vs stage/nodes, ROC AUC, overall survival HRs, and immune-infiltrate correlations including PD1
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
ITGAL was higher in GC (GEPIA p<0.05; UALCAN p=0.0015), rose with stage/nodes, discriminated GC with AUC 0.798, correlated with CD8 T cells (rho=0.732) and lower purity, and worse OS (HR 1.25 and 1.47 on two probes).
Methodology
Mined TIMER, GEPIA, UALCAN, KM plotter (1,065 GC cases), and TISIDB for ITGAL vs clinicopathology and 28 TIL types, then checked 10 paired tumors by qRT-PCR/Western blot and IHC including PD1.
Limitations
Bulk correlation is not proof that ITGAL causes immune exhaustion or that targeting it would help patients; KM plotter HRs vary by stage, and the wet-lab N is only 10 pairs.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.